Sign inJoin waitlistJoin the waitlist

Gautam Popli

Section Head, Epilepsy · Wake Forest University Baptist Medical Center

Credentials: · · · · ·

History

Epilepsy Section · Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

Epilepsy
Boston Children's Hospital
2009–2010
Child Neurology
Boston Medical Center
2006–2009
Cornell University Medical College
1995–1998
Government Medical College and Hospital
1990–1993
Netaji Subhash Chandra Bose Medical College
1986–1990

Research

Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients
Epilepsia · 2019 · 148 citations
Developing a hippocampal neural prosthetic to facilitate human memory encoding and recall
Journal of Neural Engineering · 2018 · 80 citations
Long-term outcomes of mesial temporal laser interstitial thermal therapy for drug-resistant epilepsy and subsequent surgery for seizure recurrence: a multi-centre cohort study
Journal of Neurology · 2023 · 46 citations

DC
Daniel Couture
11 papers
Adrian Laxton
8 papers
Charles Liu
4 papers
CH
Christianne Heck
4 papers
GN
George Nune
4 papers
HG
Hui Gong
4 papers
RW
Robert Wicks
4 papers · 2 as a resident
SH
Susan Huang
4 papers
Bryan Moore
3 papers
Mark Witcher
3 papers · 2 as a resident
Andrew Ko
2 papers
Ashesh Mehta
2 papers

Clinical trials

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
Site PI · Not yet recruiting · Phase 4
Azurity Pharmaceuticals
2026–2027
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
Site PI · Recruiting · Phase 1, Phase 2
Neurona Therapeutics
2024–2042
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Site PI · Recruiting · Phase 3
Neurona Therapeutics
2022–2043
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Site PI · Recruiting · Phase 3
Epygenix
2020–2029